Evidence map›Paper›PMID 36082329›Full record

ArticleHeliyon2022

Pharma 4.0: analysis on core competence and digital levelling implementation in pharmaceutical industry in Indonesia.

N Nurlaela Arief, Aurik Gustomo, M Rahman Roestan, Aghnia Nadhira Aliya Putri, Muthya Islamiaty

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

N Nurlaela AriefSchool of Business and Management, Institut Teknologi Bandung, West Java, Indonesia.
Aurik GustomoSchool of Business and Management, Institut Teknologi Bandung, West Java, Indonesia.
M Rahman RoestanSchool of Business and Management, Institut Teknologi Bandung, West Java, Indonesia.
Aghnia Nadhira Aliya PutriPT. Bio Farma, Bandung, West Java, Indonesia.
Muthya IslamiatySchool of Business and Management, Institut Teknologi Bandung, West Java, Indonesia.
Bandung Institute of Technology · IDPT Bio Farma (Indonesia) · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This paper aims to explore core competencies and analyze the digital leveling implementation of Pharma 4.0 in Indonesian Pharmaceutical companies. Method: This study uses a mixed-method Delphi study conducted in the first two rounds. The first and second rounds aimed to determine the core competencies of the Pharmaceutical Industry to face the Pharma 4.0 era. In the first round, FGD was conducted involving 12 participants, and semi-structured interviews were carried out with 10 participants in the second round. Alongside Delphi, this research also employs NVIVO as a tool for content analysis. Furthermore, in the third round, a survey was conducted to determine the leveling of the digital implementation of Pharma 4.0, involving 215 senior management participants representing 34 national pharmaceutical industries. Result: The study revealed eight core competencies needed by human capital in the pharmaceutical industry to face the Pharma 4.0 era: critical thinking, bioinformatics, entrepreneurial thinking, digital skills, intrapreneurial skills, research skills, regulatory compliance, and data ethics. Regarding digital leveling implementation, this study found five main levels: level 1 (simplification), level 2 (automatization), level 3 (integrated system), level 4 (digital transformation), and level 5 (disease prediction). This study also affirms that most of the pharmaceutical industries in Indonesia are at level 2 (mean = 4.2) and level 1 (mean = 4.0). Several pharmaceutical industries are at level 3 (mean = 3.5), and a few others are at level 4 (mean 3.2) and level 5 (mean = 1.4). Research implication: This study is the first to analyze the leveling of digital implementation in Pharma 4.0. The results showed that core competencies could be used as a benchmark to develop employee skills. This current study provides the essential data for core competency development and digital leveling implementation for the pharmaceutical industry and government in preparing Pharma 4.0.

Indexed as

Core competencyDelphi studyDigital levelling implementationIndonesiaNVIVOPharma 4.0

Identifiers

PMID36082329
PMCPMC9445282
OpenAlexW4292245715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.